Aurobindo Pharma Limited

In: Science

Submitted By stupid005
Words 1397
Pages 6
Company profile
MR.P.V.ramprasad reddy,wholetim director ,and Mr K.Nityananda reddy , voice chairman along with the team of dedicated professionals, established Aurbindo pharma limited in Hyderabad on 26 December 1986 Aurbindo pharma limited is an ISO9001;2008 and GMP certified company it is engaged in manufacturing and marketing of wide range of APL’S formulations and intermidtries in in over 102 countries around the globe with more than 100 APIs and 200 dosage forms
Aurbindo pharma limited is acknowledged market leader of APIs in manufacturing and export of pencillin cephalosporins anti-viral finished dosage forms (oral&sterile)etc and made its presence in south America, Europe, Asia, Africa, middle east, CIS and specific countries . joint ventures have been established in China Brazil and USA
Aurbindo Pharma limited manufactures and marketing of wide range of organic intermidatries, semi synthetic pencillins, sterile and non sterile pencillins, cepholasporins and formulation dosage forms with an assurance of quality and reliability by making availability of wide range of Life-saving Life-sustaining Life-enhancing health care products.
Aurbindo Pharma limited at Hyderabad India manufactures genetic pharmaceuticals and active pharmaceuticals ingredients the companies manufacturing facilities are approved by several leading regulatory agencies like USFDA, UK, MHRA, WHO, Health Cnada ,MCC South Africa ANVISA brazil. The companies robust product portfolios spread over 6 major therapeutic /product area
Encompassing antibiotics anti-Retroviral, CVS,CNS, Gastroenterological and Anti-Allergics company is making these products globally in over 100 countries
Aurbindo Pharma limited has established 12 different manufacturing units around Andhra Pradesh and an advanced research center at Bachupally ,Hyderabad to spread its technology driven scientific…...

Similar Documents

Indian Pharma Industry

...Indian Pharma Industry – an overview April 13, 2012 The demand for pharmaceutical products in India is significant and is driven by low drug penetration, rising middle-class & disposable income, increased government & private spending on healthcare infrastructure, increasing medical insurance penetration etc.    The Indian pharmaceutical industry is growing at about 8 to 9 percent annually according to “A Brief Report Pharmaceutical Industry in India,” published in January 2011. The Pharmaceutical industry in India meets around 70% of the country's demand for bulk drugs, drug intermediates, pharmaceutical formulations, chemicals, tablets, capsules, orals and injectables. There are approximately 250 large units and about 8000 Small Scale Units, which form the core of the pharmaceutical industry in India (including 5 Central Public Sector Units).    I. Current Scenario:    India's pharmaceutical market grew at 15.7 per cent during December 2011. Globally, Indiaranks third in terms of manufacturing pharma products by volume. According to McKinsey, the Pharmaceutical Market is ranked 14th in the world. By 2015 it is expected to reach top 10 in the world beating Brazil, Mexico, South Korea and Turkey. More importantly, the incremental market growth of US$ 14billion over the next decade is likely to be the third largest among all markets. The US and China are expected to add US$ 200bn and US$ 23bn respectively.     McKinsey & Company’s report, “India Pharma......

Words: 1969 - Pages: 8

Pharma

...Respected Sir/Madam, I xxxx completed Bachelors in xyz College of xyz affiliated to University, Mumbai with 50% Following this, I was involved in research and has been working as an Analyst for Plant pharmaceuticals in Quality Control Department of Alapati Pharma company. I was Kindled with an ambition of higher education that would give a desired push to my career. With a strong will to pursue my further studies in Canada, I prepared for the IELTS examination and scored 6.5 bands. I am prepared to further deepen and refine my expertise through Biotechnology Course which has led me to take admission in one of the top Colleges, Centennial College, Canada. I was brought up in a well educated family and this helped me to maintain a consistent and excellent academic record; I secured Distinction marks in SSC and Intermediate. During my Bachelors, I submitted many research papers in worldwide and India wide seminars like IPC, IPA, National seminars where 12 of my Research papers were published in Medical and Pharmacy Journals. I was also awarded a "Gold medal" for a Seminar conducted by Indian Pharmaceutical Congress which provided me a wonderful platform to meet the top heads of Pharmaceutical Industry in the country. I Started my career as an Asst. Manufacturing Chemist in Triomed Formulations India(Pvt) Ltd as soon as i was graduated. Then i opted for a Subject Knowledge Enhancement Course......

Words: 741 - Pages: 3

Pharma

...declined in at least three of the four recession struck countries and could have a negative impact on public health if used less. Further analyses of the most frequently used products in these categories did not show a consistent change in consumption with the economic recession. No individual marker products were found which could be used by governments to track their pharmaceutical consumption and the functioning of their health systems to provide early warning signs. 4 Executive summary Impact of the economic recession on the pharmaceutical sector The time span of this study was limited to one year before and two years after the recession. Many countries were already beginning to recover from the economic recession in 2010 and the value of this study for those recovered countries as a measure of the impact of the economic crisis on the pharmaceutical sector is thus limited. However there may be more to learn from this recession which could guide future policy responses to future recessions. For example some countries experienced severe declines in GDP but did not show any decline in pharmaceutical consumption. Conclusions The economic recession which began in 2008 has had a mixed effect on pharmaceutical consumption, expenditures and prices. The largest changes have occurred in high income countries and in Europe. On country level, particulary the Baltic States showed large changes in their pharmaceutical consumption, expenditure and prices. No consistent......

Words: 25253 - Pages: 102

Pharma

........................ 35 MERGER AND ACQUISITION (M&A) ACTIVITIES .................................. 36 MARKET OUTLOOK AND RECOMMENDATIONS ...................................... 38 COUNTRY PROFILES ......................................................................................... 41 COMPANY PROFILES ........................................................................................ 48 GCC Pharmaceutical Sector | March 31, 2013 Page | 3 “The pharma sector in Qatar is poised for growth over the next few years in line with the growth trend in GCC, which is the wider market segment. A major driver to this will be the projected growth in the economy. On the regulatory side, the recent legislation proposed by the Supreme Health Council towards deregulation of pharmaceutical imports to encourage free market competition is a step in the right direction. The industry is also looking forward to the proposed national health insurance program, as this is perceived to be a catalyst to growth of the pharma industry in Qatar.” Sheikh Faisal Bin Qassim Al Thani Chairman Aamal Company (Ebn Sina Pharmacy) “The GCC pharmaceutical sector has been growing steadily along with the general uptrend within the region. The pharmaceutical sector is highly regulated in nature and hence comes with its own limitations with regards to registration and entry into new markets. However, the recent trend of increased use of generics and the growth in medical insurance penetration will...

Words: 27542 - Pages: 111

Pharma Industry

... | |EUR / USD |1.2438 | |GBP / USD |1.8333 | |USD / JPY |108.1508 | |USD / CHF |1.2426 | |Source: calculated using Federal Reserve daily data | Industry Trends Here we examine structural changes causing significant transformations, major factors leading to strong future sales growth, and point out the industry’s strong reliance on research and development. Structural changes The pharmaceutical industry is currently undergoing a period of very significant transformation. The majority of “Big Pharma” companies generate high returns, thus providing them with excess cash for further rapid growth – whether organic, or through mergers and acquisitions. Although size of the company on its own does not guarantee success, it gives a significant advantage, especially in pharmaceutical industry. Besides economies of scale in manufacturing, clinical trials and marketing, bigger companies can allow investments in more research and development (R&D) projects that diversify their future drugs portfolio and make them much more stable in the long term. As the result, top-companies in the industry were active participants of mergers and acquisitions (M&A), new joint ventures and spin-offs of non-core businesses. The largest acquisitions in the......

Words: 10094 - Pages: 41

Indian Pharma Industry

...to an estimated Rs 67 billion, due to higher price competition. The largest drug class in this category is anti-peptic ulcerants. Major players include Sun Pharma and Zydus Cadila. Pain/analgesics Pain/analgesic drugs accounted for 8.1 per cent of total domestic formulations sales in 2012-13. The segment registered a CAGR of about 11.2 per cent over the last three years, reaching an estimated Rs 51 billion in 2012-13. Anti-rheumatics, non-steroids, non-narcotic anti-pyretics, anti-osteoporosis drugs, topical anti-rheumatics and muscle relaxants (systemic) are the main drug classes within this segment. Ranbaxy and GlaxoSmithKline are the leading pharmaceutical companies in this space. Chronic segments Cardiovascular system drugs Therapies for cardiovascular (CVS) ailments rely primarily on control of blood pressure and cholesterol, since high blood pressure increases the risk of heart diseases and strokes. In 2012-13, this segment was one of the fastest-growing in the domestic formulations market, posting a 14.5 per cent growth to reach Rs 76 billion. The segment constituted 12 per cent of total domestic formulation sales. Leading drug classes in this segment are statins, hypotensive combinations, anti-coagulants, diuretic combinations, calcium channel blockers and beta blockers. Key players in this therapy are Sun Pharma, Zydus Cadila and Lupin. Respiratory Sales of respiratory drugs posted a 3-year CAGR of 11 per cent, reaching an estimated Rs 51 billion in 2012-13.......

Words: 12248 - Pages: 49

Indian Pharma

...Pharmaceutical and Medical Products Practice India Pharma 2020 Propelling access and acceptance, realising true potential The report is furnished to the recipient for information purposes only. Each recipient should conduct its own investigation and analysis of any such information contained in this report. No recipient is entitled to rely on the work of McKinsey & Company, Inc. contained in this report for any purpose. McKinsey & Company, Inc. makes no representations or warranties regarding the accuracy or completeness of such information and expressly disclaims any and all liabilities based on such information or on omissions therefrom. The recipient must not reproduce, disclose or distribute the information contained herein without the express prior written consent of McKinsey & Company, Inc. 12 Executive summary India Pharma 2020: Propelling access and acceptance, realising true potential 13 Global pharmaceutical markets are in the midst of major discontinuities. While growth in developed markets will slow down, emerging markets will become increasingly important in the coming decade. The Indian pharmaceuticals market, along with the markets of China, Brazil and Russia, will spearhead growth within these markets. The Indian pharmaceuticals market has characteristics that make it unique. First, branded generics dominate, making up for 70 to 80 per cent of the retail market. Second, local players have enjoyed a dominant position driven by......

Words: 9542 - Pages: 39

Pharma

...RESEARCH PROJECT ON “TRAINING AND DEVELOPMENT IN PHARMASUITICAL INDUSTRY WITH SPECIAL REFERENCE OF MANKIND PHARMA LTD” SUBMITTED IN PARTIAL FULFILLMENT OF DEGREE OF BACHELOR OF BUSINESS ADMINISTRATION SESSION (2011-2014) SUBMITTED TO: SUBMITTED BY: XYZ XYZ BBA III University Roll No. SUBMITTED TO ACKNOWLEGDEMENT “Gratitude is the hardest of emotions to express and one often does not find adequate words to convey what one feels and trying to express it” The present project file is an amalgamated of various thoughts and experiences .The successful completion of this project report would have not been possible without the help and guidance of number of people and specially to my project guide .I take this opportunity to thank all those who have directly and indirectly inspired, directed and helped me towards successful completion of this project report. I am also immensely indebted to my project guide, MS. Divya Vaid Lecturer, ICL, for his......

Words: 8569 - Pages: 35

Pharma 2020

...www.pwc.com/pharma2020 Pharma 2020: Supplying the future Which path will you take? Pharmaceuticals and Life Sciences Previous publications in this series include: Pharmaceuticals Pharma 2020: The vision Which path will you take?* Published in June 2007, this paper highlights a number of issues that will have a major bearing on the industry by 2020. The publication outlines the changes we believe will best help pharmaceutical companies realise the potential the future holds to enhance the value they provide to shareholders and society alike. Pharmaceuticals and Life Sciences Pharma 2020: Challenging business models Which path will you take? Fourth in the Pharma 2020 series and published in April 2009, this report highlights how Pharma’s fully integrated business models may not be the best option for the pharma industry in 2020; more creative collaboration models may be more attractive. This paper also evaluates the advantages and disadvantages of the alternative business models and how each stands up against the challenges facing the industry. *connectedthinking Pharma 2020: The vision  # Pharmaceuticals and Life Sciences Pharma 2020: Virtual R&D Which path will you take? This report, published in June 2008, explores opportunities to improve the R&D process. It proposes that new technologies will enable the adoption of virtual R&D; and by operating in a more connected world the industry, in collaboration with researchers, governments, healthcare payers and......

Words: 13197 - Pages: 53

Xyz Pharma

...Project Portfolio Management at XYZ Pharma Part 1- The objectives in the Project Portfolio Management include strategically organizing the importance of different issues within the company, focus more on the sales growth rather than the sales figure, and prioritize the research and development. The constraints that take place within the case are linked to the discovery of different drugs and the risks that follow. Also, John Smith mentioned lengthening and shortening the steps of developing a new drug; which plays a factor on the developing cost and will increase significantly. Another constraint is the generic competitors. In the article it mentioned that the generic drugs to the newly made drugs can be freely sold without clinical trials. The risks involved within XYZ Pharma are mainly associated with the cost factors. It is extremely expensive to spend money on the drugs that never reach the market. Each process takes years to get through and the percentage of drugs that make it through each stage decreases each time. Stated in the case study, on average only 1 in 5 drugs that enter the clinical trials are launched onto the market. Also, if a drug doe’s make it to be sold in the market, there is only a 30% chance the drug is successful enough to recover from the development costs to yield a healthy return. Companies must rely on a limited number of highly successful products to properly finance their R&D and companies in their recent years have only been......

Words: 629 - Pages: 3

Xyz Pharma

...September 2005 Project Portfolio Management at XYZ Pharma Early morning, Monday 29th August 2005. John Smith, head of portfolio management and strategic planning, was paging through the slides he had prepared for the Portfolio Management Board (PMB) meeting which would start at 9 am, and which was scheduled to last until Friday. “We have been preparing this meeting for weeks”, he thought, “and it seems the PMB has some tough decisions to make”. The PMB of XYZ Pharma, the pharmaceutical division of XYZ, one of the world’s leading companies in the life science sector, convenes yearly in August to review the composition of the research and development (R&D) project portfolio. It also meets on a monthly basis to monitor the project portfolio and make decisions regarding new developments. According to John Smith, “The PMB is an important decision making body because it shapes the future of the company by determining its product pipeline”. The PMB members include the CEO of XYZ, the CEO of XYZ Pharma, the heads of the different business units, the heads of Development, Research, Global Marketing and Strategic Planning, the regional heads for the US, Europe and Japan and the functional managers for Regulation, Clinical, Licensing, Technical Research and Development, and Patents. The portfolio group, led by John Smith, had analysed the project portfolio carefully and had highlighted several potential threats that required action. According to John, “There will be an indepth......

Words: 5468 - Pages: 22

Pharma

...characteristics when it is these characteristics that strive to improve and develop new vaccines and drugs. Reference List Ansumana, R. et al. (2013) ‘Presumtive self-diagnosis of malaria and other febrile illnesses in Sierra Leone’ Pan African Medical Journal, Vol 15 Issue 34, pp. 2291 Bastiaens, G. J. H., Bousema, T., Leslie, T. (2014) ‘Scale-up of Malaria Rapid Diagnostic Tests and Artemisinin-Based Combination Therapy: Challenges and Perspectives in Sub-Saharan Africa’, PLoS Med, Vol 11 Issue 1. Bell, D. et al. (2006) ‘Ensuring quality and access for malaria diagnosis: how can it be achieved?’, Nature Reviews Microbiology, Vol 4 Issue 9, pp. 682-695. Berndt, E. R., Cockburn, I. M. (2014) ‘The Hidden Cost Of Low Prices: Limited Access To New Drugs In India’, Health Affairs, Vol 33 Issue 9, pp. 1567-1575. Bjorkman, A., Bhattarai, A. (2005) ‘Public health impact of drug resistant Plasmodium falciparum malaria’, Acta Trop, Vol 94, pp. 163–169. Bond, E. W., Saggi, K. (2014) ‘Compulsory licensing, price controls, and access to patented foreign products’, Journal of Development Economics, Vol 109, pp. 217–228. Chene, M. (2010) ‘U4: Anti-Corruption Resource Centre. Overview of corruption and anti-corruption in Sierra Leone’, Transparency International, Number 256, [Online] http://www.u4.no/publications/overview-of-corruption-and-anti-corruption-in-sierra-leone/ (Accessed: 15th October 2014). Gates, B., Gates, M. (2014) Annual Letter. Bill and Melinda......

Words: 2477 - Pages: 10

Beximco Pharma

... Executive Summary After growing at a robust twenty plus percentage in 2010 and 2011, Bangladesh Pharmaceutical Industry experienced a slower growth in 2012. The market grew by 11.9% in value terms to reach at Tk. 94 billion (IMS: Q4 2012 report). Despite a slower growth in the market, Beximco Pharma managed to achieve desired growth and successfully improve its market share. The country continued to maintain 6% plus GDP growth rate in 2012 as well. The alarming depreciation of Taka against US Dollar that continued throughout 2011 till January 2012 has finally been restrained. Thanks to higher inward remittances, lower payment for import settlements, and moderate growth in export. The local currency appreciated by around 2.5% against US Dollar in 2012. This was somewhat a relief to the predicted risk of significant reduction of gross margin that started brewing in 2011 in the wake of deteriorating value of local currency against US Dollar, high rate of domestic inflation and increase in the interest rates. The liquidity shortage that prevailed throughout 2011 also eased up to some extent in 2012. However, the political crisis that started by end of 2012 centering the upcoming election poses some degree of uncertainty in the overall economic environment of the country and is seen as an impediment to the growth of business. The first quarter of 2013 has already been affected for such instability in the political environment and continues to remain as a risk factor. ...

Words: 5929 - Pages: 24

Pharma

...www.pwc.com/us/pharma Aspiring giants How small pharmas can drive to $1 billion — and beyond PwC’s PRTM Management Consulting Aspiring giants Executive summary Amid the volatile blend of opportunity and challenge that characterizes the global pharmaceutical industry, only a few small companies have managed to catapult their revenue over the $1 billion mark over the past two decades. Whether they chose to expand their therapeutic area focus and product portfolios, enter new geographies, or grow their core business, these aspiring giants pursued three distinct strategies to jump-start growth:  Leveraged core product and technology capabilities to launch differentiated products  Used mergers and acquisitions to gain new products and/or expand geographic presence  Built a strong, stable leadership team armed with a compelling vision and relentless drive The experiences of these winning companies offer lessons for today’s smaller pharma companies harboring the ambition to reach the $1 billion revenue mark. To achieve this milestone, these companies will need to excel in three areas: expanding a core area of expertise to deliver niche and valueadded products, adopting an acquisition and partnering mindset to expand product offerings and geographic presence, and attracting and retaining talented leaders. Focusing on these fronts can help position a pharma company to become a growth leader—rather than merely a follower—in......

Words: 4167 - Pages: 17

Global Pharma Industry

...Pharmaceuticals and Life Sciences Global pharma looks to India: Prospects for growth Table of contents Introduction 03 Background 04 A fast growing economy An expanding pharmaceutical market Government-provided healthcare improving, but private healthcare dominates Domestic market overview 09 Background Consolidation underway, despite challenges Contract manufacturing Vaccines Over the counter market holds significant potential Reaching the untapped rural market Growing Research & Development 15 Overview Clinical trials Biotech and biosimilars on track for growth Other growth areas Bioinformatics 20 Stem cell research Medical devices Global Pharma’s evolving business models and options in India 23 Background Export-oriented business (Contract Research and Manufacturing Services) Licensing Franchising Joint ventures Wholly-owned subsidiaries Practical concerns 27 Infrastructure Tax environment Counterfeiting Intellectual property Conclusion 30 Related reading: Pharma 2020 31 References 32 Acronyms 38 Introduction The pharmaceutical industry’s main markets are under serious pressure. North America, Europe and Japan jointly account for 82% of audited and unaudited drug sales; total sales reached US$773 billion in 2008, according to IMS Health. Annual growth in the European Union (EU) has slowed to 5.8%, and sales are increasing at an even more sluggish......

Words: 17333 - Pages: 70